search
EADV Congress
Trends
- 1EADV 2026 Day 4 Spotlights Precision Medicine and Real-World Evidence●EADV 2026 Day 4: Precision Medicine, Real-World Evidence, and the Future of Dermatologic Care
Day 4 of the EADV 2026 Congress is drawing attention for its focus on precision medicine and real-world evidence in dermatology. Coverage highlights how personalised treatment approaches and data from everyday clinical practice are shaping the future of dermatologic care, with sessions exploring what these trends mean for patients and clinicians.
- 2EADV Congress 2026: Day 3 Highlights and Key Takeaways▼EADV Congress 2026: Day 3 Recap—5 Headlines to Know
Day 3 of the European Academy of Dermatology and Venereology (EADV) Congress 2026 produced five headline developments, according to a recap published by medical news outlet HCPLive. The roundup gathers the day's most notable dermatology research, trial results and clinical announcements for clinicians following the meeting. Details of the specific studies were not included in the available coverage.
- 3Climate Change Tied to Shifts in Skin Disease Worldwide▼Climate Change Linked to Skin Disease Changes Worldwide: EADV 2026
Research presented ahead of the EADV 2026 congress links climate change to changes in skin disease patterns worldwide. The report, covered by the European Medical Journal, suggests rising temperatures and environmental shifts are affecting how dermatological conditions emerge and spread globally. Details of the findings remain limited, and dermatology experts are expected to discuss the evidence at the European Academy of Dermatology and Venereology meeting.
- 4EADV Congress 2026: Day 2 Roundup of Key Headlines▼EADV Congress 2026: Day 2 Recap—6 Headlines to Know
The European Academy of Dermatology and Venereology's 2026 congress continued into its second day, with a recap highlighting six headline developments from the meeting. Coverage focuses on the key research presentations, clinical updates, and announcements emerging from the event, giving dermatology specialists a digest of the most notable news so far.
- 5EADV Congress 2026 Opens With Six Key Headlines▼EADV Congress 2026: Day 1 Recap — 6 Headlines to Know
The European Academy of Dermatology and Venereology has begun its 2026 Congress, with day one yielding six headline developments in dermatology and venereology. Coverage highlights new clinical findings and treatment updates presented at the meeting, which brings together skin-health specialists from around the world. Attendees and medical media are summarising the most notable announcements as the congress continues.
- 6New Rezpegaldesleukin Data Shows Durable Results at EADV 2026▼New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
New clinical data for rezpegaldesleukin, an immune-regulating drug candidate, show long-term durability and disease improvement in patients with alopecia areata and atopic dermatitis. The findings are being presented at the EADV Congress 2026, Europe's major dermatology meeting. The data support the treatment's potential for these chronic inflammatory skin conditions, where maintaining improvement over time remains a key challenge for patients and physicians.
- 7Two-Year Data for Alopecia Drug LEQSELVI Shows Sustained Efficacy▼New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026
Sun Pharmaceutical announced two-year clinical data for LEQSELVI (deuruxolitinib) in severe alopecia areata, presented at the EADV Congress 2026. The results showed sustained efficacy and a consistent safety profile in patients over the extended treatment period. The findings reinforce the drug's long-term value for people with severe hair loss, though discussion so far appears limited to the announcement itself.
- 8New Biomarker Data on Rezpegaldesleukin Presented at EADV Congress 2026●New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
New biomarker data on rezpegaldesleukin were presented in a late-breaking oral presentation at the EADV Congress 2026. The findings show early molecular responses to the drug across multiple immune pathways that are dysregulated in patients with atopic dermatitis. The data suggest the therapy, an immune-regulating treatment, is being positioned as a potential option for the inflammatory skin condition, and the presentation is drawing attention from the dermatology community.
- 9CytoAgents Unveils New Preclinical Data on CTO1681●CytoAgents Presents New Preclinical CTO1681 Data at the 2026 EADV Congress
CytoAgents presented new preclinical data on its investigational compound CTO1681 at the 2026 EADV Congress, the European Academy of Dermatology and Venereology's annual meeting. The company says the findings support the drug candidate's development potential in dermatology. Details of the data and the indication being targeted have not been broadly reported, and the announcement is drawing attention from investors and dermatology specialists following the congress presentation.